Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Single Dose Crossover Comparative Bioavailability Study of Bupropion Hcl MR Tablet 300mg
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Alembic Pharmaceuticals Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT05160090
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
🇨🇦Algorithme Pharma Inc., Mount-Royal, Quebec, Canada
Oral Bio-equivalence Study
- Conditions
- SafetyBioequivalence
- Interventions
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Alembic Pharmaceuticals Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05145621
- Locations
- 🇨🇦
Algorithme Pharma Inc., Mount-Royal, Quebec, Canada
Comparative Bioavailability Study of Lamotrigine ER Tablets USP 50 mg
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Alembic Pharmaceuticals Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT05145608
- Locations
- 🇨🇦
Algorithme Pharma, Mount Royal, Quebec, Canada
News
Alembic Pharmaceuticals Receives FDA Approval for Generic Tretinoin Cream to Treat Acne Vulgaris
Alembic Pharmaceuticals has received final FDA approval for its generic Tretinoin Cream USP (0.025%) to treat acne vulgaris in the US market.
Alembic Pharmaceuticals Acquires UTILITY Therapeutics to Commercialize First New UTI Antibiotic in 20 Years
Alembic Pharmaceuticals has acquired UTILITY Therapeutics to expand its U.S. commercial portfolio with PIVYA, the first antibiotic approved for uncomplicated urinary tract infections in approximately 20 years.
Alembic Pharmaceuticals Receives FDA Approval for Generic Ticagrelor Tablets to Reduce Cardiovascular Risks
Alembic Pharmaceuticals has secured final FDA approval for Ticagrelor Tablets 90 mg and tentative approval for the 60 mg version, a generic equivalent to AstraZeneca's Brilinta.
Alembic Pharma Shares Surge Following USFDA Clearance of Panelav Oncology Facility
Alembic Pharmaceuticals received an Establishment Inspection Report (EIR) from the USFDA for its Panelav oncology formulation facility following a clean inspection conducted from October 7-8, 2024.
FDA Approves 25 First-Time Generic Drugs in First Half of 2025, Expanding Access to Critical Therapies
The FDA approved 25 first-time generic drugs in the first six months of 2025, including generics for critical medications treating HIV, cancer, and neurological conditions.
Alembic Pharmaceuticals Secures USFDA Approvals for Carbamazepine and Amlodipine-Atorvastatin Generics
Alembic Pharmaceuticals has received final USFDA approval for generic Carbamazepine 200 mg tablets, an anticonvulsant used for seizure disorders and neuropathic pain with a US market size of approximately $32 million.
Alembic Pharmaceuticals Receives FDA Approval for Pantoprazole Sodium Injection to Treat GERD
Alembic Pharmaceuticals has secured final USFDA approval for Pantoprazole Sodium for Injection (40 mg/vial), therapeutically equivalent to Wyeth's Protonix I.V. for Injection.
Allchem Lifescience Files for IPO to Raise ₹190 Crore, Expands API Manufacturing Capabilities
Gujarat-based Allchem Lifescience has filed preliminary IPO papers with SEBI, seeking to raise ₹190 crore through fresh equity shares and an offer for sale of 71.55 lakh shares by promoters.
Alembic Pharmaceuticals Receives US FDA Approval for Diltiazem Hydrochloride Extended-Release Capsules
Alembic Pharmaceuticals has secured US FDA approval for Diltiazem Hydrochloride extended-release capsules (120 mg, 180 mg, 240 mg, 300 mg, and 360 mg).
Alembic Pharmaceuticals Receives USFDA Approval for Generic Hypertension Treatment
Alembic Pharmaceuticals has secured USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules, used to treat hypertension.